News & Publications

Britain’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service cover Bavencio (avelumab) as a treatment for adults with metastatic Merkel cell carcinoma (mMCC), a rare form of skin cancer. The institute’s Final Appraisal Determination (FAD) re...

BACKGROUND: Merkel cell carcinoma (MCC) incidence rates are rising and strongly age-associated, relevant for an aging population. OBJECTIVE: Determine MCC incidence in the United States and project incident cases through the year 2025. METHODS: Registry data were obtained from the SEER-18 Database, ...

MISSISSAUGA, ON, Feb. 22, 2018 /CNW/ - EMD Serono, Canada, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, and Pfizer Canada Inc. announced that Health Canada has approved BAVENCIOâ„¢ (avelumab for injection) for the treatment of metastatic Merkel cell carcin...

On February 16, 2018, UW Medicine released an article on the projected increase for cases of Merkel cell carcinoma in the United States. This rare, aggressive cancer is rising nearly six times faster than other cancers. Current studies show that the incidence is expected to exceed 3,025 cases by 202...

Aim: The aim of this article was to provide worldwide, population-based incidence rates for Merkel cell carcinoma (MCC). Methods: We included 11,576 cases from 20 countries for time trend analyses (1990e2007) and 11,028 cases (2.5 billion person-years) from 21 countries for the period 2003e2007 extr...

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human antiâ€...

The University of Washington Newsletter recently published the story of Robert Yolles-- a husband whose ultimate goal was to help his wife, Monica, find the best possible doctors and treatments for her Merkel cell carcinoma. Through his search, he found Dr. Paul Nghiem. To this day, Yolles remains c...

PURPOSE: Patients presenting with nodal Merkel cell carcinoma without an identifiable (unknown) primary lesion (MCC-UP) are nearly twice as likely to survive compared to similarly staged patients with known primary lesions (MCC-KP). The basis of this previously reported finding is unclear. EXPERIMEN...

Merkel cell carcinoma (MCC) is a rare (~2,000 US cases/year) but aggressive neuroendocrine tumor of the skin. For advanced MCC, cytotoxic chemotherapy only infrequently (1 year) suggesting a great need for improved therapeutic options. In 2008, the Merkel cell polyomavirus (MCPyV) was discovered and...

Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations af...